We present a case of utilizing pseudo-autologous hematopoietic SCT (pASCT) as a treatment for relapse following allogeneic hematopoietic SCT (alloSCT) in a patient with multiple myeloma.
A 39-year-old female was diagnosed with Durie-Salmon stage 2A, IgG lambda multiple myeloma in May 1997. As definitive treatment, she underwent a fully ablative alloSCT with her HLA-matched (6/6 Ag) male sibling as the donor in August 1997. BM with a cell dose of 3.1 Â 10 8 nucleated cells/kg was infused. She developed Grade I gut GVHD and Grade II skin GVHD, which responded well to CYA and methylprednisolone. Long-term complications included mild chronic GVHD involving skin and vagina, but active GVHD had disappeared by 3 years after the transplant and she returned to normal life. In August 2009, 12 years after alloSCT, the previously identified paraprotein reemerged. She was observed for 1 year before initiation of treatment. A BM aspirate showed 1% plasmacytosis, but rare patchy aggregates of plasma cells were also seen. FISH analysis revealed all cells to have a male karyotype (XY). Treatment with lenalidomide and dexamethasone was initiated. Unfortunately, she was admitted to hospital for hypoxia after two cycles. A computed tomography scan chest showed bilateral infiltrates and reactive lymphadenopathy. Testing for infectious etiologies was negative, and a bronchoscopy was unremarkable. Her symptoms quickly responded to prednisone. The cause of the hypoxia was believed to be an interstitial pneumonitis reaction to lenalidomide but pulmonary GVHD could not be excluded. Further therapy with lenalidomide was felt to be contraindicated.
Retreatment with high-dose melphalan was considered, given the prolonged first remission with the initial transplant. Possible sources of stem cells included the sibling donor as well as the patient. Concerns regarding the possibility of GVHD and requirement for immunosuppression were raised. It was decided to use pseudo-autologous peripheral blood stem cells from the patient without immunosuppression, with the rational that these stem cells had developed tolerance such that the risk of GVHD would be low. With filgrastim only as stimulation, a dose of 3.57 Â 10 6 CD34 þ cells/kg pseudo-autologous peripheral blood stem cells were collected. She received melphalan 200 mg/m 2 followed by pASCT in late August 2011. The post-transplant course was complicated by typhilitis and neutropenic fevers. A rash was seen around the time of engraftment. Skin biopsy was consistent with drug eruption, and not GVHD. No other signs of GVHD were seen. Her post-transplant course was otherwise unremarkable with full engraftment by day þ 13. Currently, she remains well and is on no anti-myeloma therapy, although a small paraprotein is present in her serum.
Before the availability of novel agents, alloSCT was offered to eligible patients at our center as definitive treatment. Unfortunately, relapse is a major cause of treatment failure. Our case serves to illustrate a treatment option for such patients who will eventually die of myeloma. We are unaware of such a case in the literature, although there has been reported a similar case of a BM donor who developed a hematological malignancy, who subsequently underwent a transplant with the recipient now acting as the donor. 1 For our case, the option of using either the donor or the patient as the source of stem cells for the pASCT adds to the intricacies of the situation.
For patients with myeloma who relapse following an alloSCT, novel agents are important treatment options, although complications may arise. The use of lenalidomide as treatment following alloSCT has been reported; 2 however, there was an increased risk of GVHD stimulation. 3 For these reasons, lenalidomide must be used with caution. Eventually, all drug-treatment options fail, for which reason the possibility of using high-dose melphalan for patients who have had long first remissions is an important option to consider.
